Unfortunately, the complete response (CR) rate in diffuse large B cell lymphoma (DLBCL) subgroup was only 29%, which is lower than that reported for CD19-CAR T-cell therapy (39–65%)5. This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.